News on Innovation Biotech Co.%2C Ltd. from BioPortfolio.com http://www.BioPortfolio.com Consolidated Innovation Biotech Co.%2C Ltd. news from BioPortfolio.com Tue, 09 Feb 2010 23:15:03 GMT en Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033853&HITNO=0&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033853&THISHREF=http://c.moreover.com/click/here.pl%3fz2535445039%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033853&HITNO=0&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033853&THISHREF=http://c.moreover.com/click/here.pl%3fz2535445039%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Online: Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033171&HITNO=1&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033171&THISHREF=http://c.moreover.com/click/here.pl%3fz2535047334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033171&HITNO=1&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033171&THISHREF=http://c.moreover.com/click/here.pl%3fz2535047334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWeb Newswire: Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033015&HITNO=2&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033015&THISHREF=http://c.moreover.com/click/here.pl%3fz2534953777%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033015&HITNO=2&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033015&THISHREF=http://c.moreover.com/click/here.pl%3fz2534953777%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWebWire: BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036316&HITNO=3&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036316&THISHREF=http://c.moreover.com/click/here.pl%3fz2536569406%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036316&HITNO=3&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036316&THISHREF=http://c.moreover.com/click/here.pl%3fz2536569406%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035372&HITNO=4&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035372&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035372&HITNO=4&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035372&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comLos Angeles Chronicle: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033945&HITNO=5&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033945&THISHREF=http://c.moreover.com/click/here.pl%3fz2535503644%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033945&HITNO=5&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033945&THISHREF=http://c.moreover.com/click/here.pl%3fz2535503644%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Chronicle: Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033189&HITNO=6&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033189&THISHREF=http://c.moreover.com/click/here.pl%3fz2535053908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033189&HITNO=6&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033189&THISHREF=http://c.moreover.com/click/here.pl%3fz2535053908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Israeli Teva gets rights for multiple sclerosis drug in Nordic, B...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036541&HITNO=7&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036541&THISHREF=http://c.moreover.com/click/here.pl%3fz2536650609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036541&HITNO=7&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036541&THISHREF=http://c.moreover.com/click/here.pl%3fz2536650609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Cell Biotech Co., Ltd-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034015&HITNO=8&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034015&THISHREF=http://c.moreover.com/click/here.pl%3fz2535560658%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034015&HITNO=8&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034015&THISHREF=http://c.moreover.com/click/here.pl%3fz2535560658%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Celtic Biotech Ltd.-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033924&HITNO=9&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033924&THISHREF=http://c.moreover.com/click/here.pl%3fz2535488854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033924&HITNO=9&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033924&THISHREF=http://c.moreover.com/click/here.pl%3fz2535488854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: ProCognia CEO not disappointed with NIS 6.4m offering: The biotech company had hoped to raise NIS 11 millionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033563&HITNO=10&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033563&THISHREF=http://c.moreover.com/click/here.pl%3fz2535271882%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033563&HITNO=10&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033563&THISHREF=http://c.moreover.com/click/here.pl%3fz2535271882%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Israeli Teva gets rights for multiple sclerosis drug in Nordic, Baltic stateshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036829&HITNO=11&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036829&THISHREF=http://c.moreover.com/click/here.pl%3fz2536778593%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036829&HITNO=11&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036829&THISHREF=http://c.moreover.com/click/here.pl%3fz2536778593%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comM2: Teva acquires marketing rights for oral laquinimod in the nordic and baltic regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034216&HITNO=12&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034216&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682140%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034216&HITNO=12&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034216&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682140%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034215&HITNO=13&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034215&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682088%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034215&HITNO=13&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034215&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682088%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Updates for PPD (Nasdaq:PPDI), Repros Therapeutics (Nasdaq:RPRX), Stem Cell Therapy (OTC:SCII)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035374&HITNO=14&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035374&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217918%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035374&HITNO=14&MSIZE=601&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Innovation%20Biotech%20Co.,%20Ltd.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035374&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217918%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comLos Angeles Chronicle: